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SUMMARY
Objective: To study the efficacy, safety, and feasibility of stent-assistant angioplasty 
(SAA) in the treatment of symptomatic vertebrobasilar artery stenosis in the elderly. 
Methods: SAA was performed in 26 elderly patients with symptomatic vertebrobasilar 
artery stenosis. The success rate, perioperative complications, and long-term effective-
ness were evaluated. Results: A total of 29 balloon expandable stents were implanted 
in these patients. The success ratio was 100%. The degree of stenosis decreased from 
81.3 ± 8.8% to 3.7 ± 3.6% (p < 0.01). Complications were absent during the periopera-
tive period. Follow-up was performed for seven to 36 months (median: 21.9 months). 
Two patients developed the recurrent symptoms of vertebrobasilar artery stenosis, and 
no cerebral ischemic events were noted in the remaining patients, suggesting a favorable 
outcome. Conclusion: SAA is a safe and effective strategy for the treatment of symptom-
atic vertebrobasilar artery stenosis in the elderly. 
Keywords: Stent-assistant angioplasty; vertebrobasilar artery stenosis; complication; 
therapy.
RESUMO
O tratamento da estenose da artéria vertebrobasilar sintomática com 
stent-assistente de angioplastia no idoso abstrato
Objetivo: Estudar a eficácia, segurança e viabilidade de angioplastia stent-assistente 
(SAA) no tratamento da estenose da artéria vertebrobasilar sintomática em doentes ido-
sos. Métodos: SAA foi realizada em 26 pacientes idosos com estenose da artéria verte-
brobasilar sintomática. A taxa de sucesso, complicações perioperatórias e eficácia a longo 
prazo foram avaliadas. Resultados: Um total de 29 stents expansíveis por balão foram 
implantados nesses pacientes. O índice de sucesso foi de 100%. O grau de estenose foi 
reduzida de 81,3 ± 8,8% para 3,7 ± 3,6% (p < 0,01). Complicações estiveram ausentes 
durante o período perioperatório. O acompanhamento foi realizado durante 7-36 meses 
(mediana: 21,9 meses). Dois pacientes desenvolveram sintomas recorrentes de estenose 
da artéria vertebrobasilar. Eventos isquêmicos cerebrais não foram observados no res-
tante dos pacientes, sugerindo resultado favorável. Conclusão: Conclui-se que SAA é 
uma estratégia segura e eficaz para o tratamento da estenose da artéria sintomática ver-
tebrobasilar em idosos.
Unitermos: Angioplastia stent-assistente; estenose da artéria vertebrobasilar; complica-
ções; terapia.
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INTRODUCTION 
Symptomatic vertebrobasilar artery stenosis (SVAS) is an 
important cause of posterior circulation ischemia. Tradi-
tional treatments for SVAS are usually unlikely to achieve 
long-lasting effectiveness and the prognosis of SVAS is of-
ten poor1,2. The selection of a proper therapeutic strategy 
for SVAS has been challenging clinicians. In recent years, 
stent-assistant angioplasty (SAA) has been introduced for 
the treatment of cerebrovascular diseases. SAA can re-
canalize the blood vessels, increase the cerebral blood flow 
(CBF), and reduce the incidence of stroke3,4. The present 
study retrospectively reviewed the clinical records of 26 el-
derly patients with SVAS who did not responded to phar-
macotherapy and received SAA in this hospital. 
PATIENTS AND METHODS 
GENERAL INFORMATION 
A total of 26 elderly SVAS inpatients aged 72.1 ± 3.9 years 
were recruited from the Department of Neurology from 
May 2008 to October 2010. Before admission, the risk 
factors of stroke were controlled in these patients with 
anti-platelet aggregation therapy and plaque stabiliza-
tion therapy (statins). The group comprised 11 males 
and 15 females with a mean age of 72.1  ±  3.9 years 
(range: 65-78 years). 12 patients were characterized by 
transient ischemic attack (TIA) of vertebrobasilar system 
and 14 by posterior circulation infarct (POCI). Digital 
subtraction angiography (DSA) revealed stenosis in the 
first part of the vertebral artery (n = 16), V4 segment of 
the vertebral artery (n  =  3), and basilar artery (n  =  7). 
This study was approved by the ethics committee of 
Hangzhou Third People’s Hospital. All patients met the 
indications for SAA and an informed consent was ob-
tained before surgery. 
The indications for SAA included: 1) patients were 
aged ≥  60 years; 2) patients had symptomatic SVAS 
(TIA of vertebrobasilar system or non-disabling isch-
emic stroke), the degree of stenosis in DSA was > 50%, 
and patients had concomitant contralateral occlusion; 
3) the degree of stenosis in the dominant side was > 50%; 
4) the vertebral artery stenosis was also found in the non-
dominant side and this vertebral artery was connected to 
the posterior inferior cerebellar artery – the symptoms 
were related to the insufficient blood supply of the ipsi-
lateral posterior inferior cerebellar artery; (5) the degree 
of stenosis of the basilar artery was >  50%; 6) patients 
and/or relatives accepted the SAA and patients were 
compliant to the treatment. Contra-indications included: 
1) patients with residual severe neurological dysfunction 
after stroke; 2) patients with concomitant severe liver, 
heart, kidney or lung diseases/failure; 3) patients with 
complete vascular occlusion; 4) patients who developed 
intracranial hemorrhage or internal bleeding within 3 
months prior to surgery, or had hemorrhagic tendency; 
5) patients with intracranial aneurysm or arteriovenous 
malformation which could not be managed before or 
during the SAA; 6) patients with intracranial tumors. 
TREATMENT 
Three days before surgery, oral aspirin (100 mg/d), clopi-
dogrel (75 mg/d), and atorvastatin (20 mg/d) were ad-
ministered, and patients fasted for 6 h before surgery. 
Extra-cranial angioplasty was performed under local 
anesthesia and intra-cranial angioplasty under general 
anesthesia. Patients were routinely monitored with an 
electrocardiogram monitor. Right femoral artery punc-
ture was performed with modified Seldinger technique; 
subsequently, a 6F arterial sheath was inserted. Systemic 
heparinization was performed with 5000 U of intrave-
nous heparin. A 6F guiding tube was inserted along the 
arterial sheath. Under the direction of a guiding wire, 
the top of a guiding tube was inserted into the 1~2 cm 
proximal to the affected vessels. When the lesions were 
located at the beginning part of the vertebral artery, the 
top of guiding tube was inserted into the subclavian ar-
tery; when the lesions were located at the intracranial 
segment of the vertebral artery and basilar artery, the 
guiding tube was inserted into the affected vertebral ar-
tery. Then, the balloon expandable stent was guided into 
the lesioned artery, and released once the location was 
confirmed. Subsequently, angiography was carried out 
to detect the location of the stent, its relation with the 
blood vessel wall, forward blood flow, and the improve-
ment of stenosis. When the expansion of the stent was 
not acceptable, an intra-stent expansion was performed. 
The arterial sheath was remained and the heparin was 
naturally neutralized. Four hours later, the arterial sheath 
was removed. Post-operatively, the vital signs were moni-
tored and the symptoms and signs of the nervous system 
were observed. Oral aspirin (100 mg/d) and clopidogrel 
(75 mg/d) were administered for three consecutive 
months. Thereafter, the aspirin was discontinued and clop-
idogrel (75 mg/d) was given for maintenance. All patients 
were treated with atorvastatin 20 mg/d continuously. 
EVALUATION OF THERAPEUTIC EFFICACY 
MEASUREMENT OF STENOSIS DEGREE
The evaluation of stenosis was performed according to the 
North American Sypmptomatic Carotid Endarterectomy 
Trial (NASCET) criteria5. The luminal diameter at the point 
of greatest stenosis (Dsten) and at the normal part of the ar-
tery (Ddist) was measured, and the degree of stenosis was 
calculated as follows: S  =  [1-  (Dsten/Ddist)]  ×  100%. DSA 
was performed before surgery and immediately after sur-
gery for the evaluation. In addition, DSA or CTA was per-
formed for re-examination six to 24 months after surgery. 
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MEASUREMENT OF BLOOD FLOW VELOCITY AT THE STENOTIC  
LESIONS
Transcranial Doppler (TCD) was employed to measure the 
blood flow velocity. The media velocity (Vm) at the point 
of greatest stenosis was measured before surgery and one 
week as well as three, six, 12, and 24 months after surgery. 
EVALUATION OF CLINICAL EFFICACY
The success rate and the incidence of perioperative compli-
cations were determined. For the 12 TIA patients, TIA was 
monitored post-operatively. For 14 patients with cerebral 
infarction, the National Institutes of Health Stroke Scale 
(NIHSS)6 was employed to assess the neurological func-
tion at admission, discharge, and one day after surgery. 
FOLLOW-UP 
For the 26 patients receiving SAA, the score system of 
Malek et al.7 was used to evaluate the clinical efficacy. 
Malek’s assessment is divided into five scores - 1 (the best): 
no neurological deficit and no vertebrobasilar ischemic 
symptoms during the follow-up period; 2 (good): no neu-
rological deficit, and vertebrobasilar TIA does not exceed 
one in three months; 3 (better): a slight neurological defi-
cit, vertebrobasilar TIA does not exceed one per month; 
4 (poor): no improvement in neurological deficit or ver-
tebrobasilar ischemic symptoms are not relieved; 5: any 
cause of death. During the follow-up period, TIA, stroke, 
and death were recorded. Evaluation was performed at 
three, six, 12, and 24 months after surgery. Follow-up was 
performed through hospital visit with the same clinician. 
STATISTICAL ANALYSIS 
The Statistical Package for Social Sciences (SPSS) 10.0 was 
used for statistical analysis. Data were expressed as mean ± 
standard deviation. Variance analysis (one-way ANOVA) 
was used in group while the Q test (post-hoc multiple 
comparisons between groups were made with LSD) was 
used between groups. A p-value < 0.05 was considered sta-
tistically significant.
RESULTS 
CLINICAL EFFICACY AND PERI-OPERATIVE COMPLICATIONS  
In the present study, a total of 29 stents were inserted: ten 
Genesis stents, two Cypher stents, seven Intec stents, and 
ten Apollo stents. As shown in Figures 1A, 1B, 1C, and 1D, 
the success rate was 100%. Before surgery, the mean degree 
of stenosis was 81.3 ± 8.8% (range: 65%~95%). After sur-
gery, the mean degree of stenosis decreased to 3.7 ± 3.6% 
(range: 0%~10%). The degree of stenosis was significantly 
improved (p < 0.01). For 14 patients with cerebral infarc-
tion, the neurological function was markedly improved, 
and the NIHSS score6 decreased remarkably (p < 0.01). On 
discharge, the neurological function of these patients was 
further improved but similar to that of one day after sur-
gery. Before discharge, ischemia-related symptoms were 
not found, and the deterioration of original symptoms was 
also absent. TIA was not noted among these patients after 
surgery. During the perioperative period, no severe com-
plications were found.  
BLOOD FLOW VELOCITY AT THE POINT OF GREATEST STENOSIS 
The blood flow signals in TCD were satisfactory in all 
patients. The blood velocity (Vm) before surgery and 
one week, and three, six, 12, and 24 months after sur-
gery is presented in Table 1. Results showed the Vm of 
stenotic arteries was extremely high before surgery, but 
dramatically reduced after surgery and remained in nor-
mal range. Significant difference was found in the Vm be-
tween before and after surgery (p < 0.01). However, the 
Vm was similar at one week, and three, six, 12, and 24 
months after surgery (p > 0.05). 
  
FOLLOW-UP  
The median follow-up period was 21.9 months 
(range: 7~36 months). The results showed that there were 
23 patients with Malek score7 of 1, two with Malek score 
of 2, and one with Malek score of 3. For one patient with 
vertebral artery stenosis and TIA, the degree of residual 
Figure 1 – The stenosis of the vertebral artery and the clinical efﬁcacy. Before surgery, ostial stenosis degree of the vertebral 
artery was 85% (A); after surgery, it was 0% (B). Before surgery, V4 stenosis degree of the vertebral artery was 90% (C); 
after surgery, it was 10% (D). 
A B C D
TREATMENT OF SYMPTOMATIC VERTEBROBASILAR ARTERY STENOSIS WITH STENT-ASSISTANT ANGIOPLASTY IN THE ELDERLY
425Rev Assoc Med Bras 2012; 58(4):422-426
stenosis was 10%, TIA occurred once at seven months af-
ter surgery, and the symptoms of TIA were similar to those 
before surgery. Re-examination with DSA showed that the 
degree of stenosis was still 10%, and anti-platelet/coagula-
tion therapy was then performed without occurrence of 
TIA afterwards. For one patient with cerebral infarction, 
the pre-operative stenosis degree was 92% and the NIHSS 
score was 9. Immediately after surgery, the degree of steno-
sis was 10% and the NIHSS score was 4. On discharge, the 
NIHSS was 1. However, 16 months after surgery, the initial 
symptoms deteriorated and the NIHSS score was 6 on re-
examination. DSA showed that the degree of stenosis was 
similar to that immediately after surgery. Intensive therapy 
was carried out and the patient achieved remission. Of the 
remaining patients, new ischemia-related symptoms and 
deterioration of initial symptoms were absent, and TIA 
and death were not observed. 
Of note, five patients received re-examination with 
DSA, of whom two were found to have developed stenosis 
(28.6%) at the first part of arteries. The remaining 19 pa-
tients were examined with CTA. Stent migration and frac-
ture, and re-stenosis were not found. The forward blood 
flow was acceptable. 
DISCUSSION 
The traditional treatments for SVAS include pharmaco-
therapy and surgical intervention. However, the risk for 
stroke is still relatively high in vertebrobasilar artery ste-
nosis patients receiving routine pharmacotherapy, and 
the prognosis of these patients is still poor. The warfarin-
aspirin symptomatic intracranial disease (WASID) study 
demonstrated that the incidence of stroke events in the 
region supplied by the stenotic arteries was still high even 
though the patients were treated with warfarin or aspirin8. 
The annual incidence of stoke due to stenosis of basilar ar-
tery, vertebral artery, posterior cerebral artery, and poste-
rior inferior cerebellar artery was 10%, 7%, 7.8%, and 6%, 
respectively. Rasmussen et al.9 reported that approximately 
25% to 30% of patients with vertebrobasilar TIA had in-
creased incidence of fatal events and elevated mortality 
and disability. In the present study, 26 patients received 
pharmacotherapy with statins and/or antiplatelet drugs to 
control the risk factors of stroke before admission, but the 
response was poor. These results demonstrate that phar-
macotherapy cannot improve the stenosis fundamentally. 
In addition, the surgical intervention for stenosis has 
complicated procedures and potential complications, 
which significantly limits the wide application of surgi-
cal intervention. In recent years, with the development of 
neurological intervention techniques and interventional 
materials, SAA has been an effective strategy for the treat-
ment of vertebrobasilar artery stenosis due to the minimal 
invasion and high effectiveness10,11. In the present study, a 
total of 29 lesions in 26 patients were treated with SAA, 
achieving a success rate of 100%. The clinical symptoms 
and signs were significantly improved, showing favorable 
short-term therapeutic effectiveness. Moreover, these pa-
tients were followed-up for seven to 36 months (median: 
21.9 months). Results showed that there were 23 patients 
with Malek score of 1, two with Malek score of 2, and 
one with Malek score of 3, which indicates that the inter-
mediate and long-term effectiveness are also high.
The SAA for the stenotic arteries can re-canalize the 
arteries, improve the blood supply, elevate the perfusion 
of the brain tissues, and alleviate the symptoms. In addi-
tion, the stent can prevent the atherosclerotic plaque from 
breaking and reduce the risk for stroke due to falling of 
the atherosclerotic plaque. In the present study, the de-
gree of stenosis in these patients was 81.3 ± 8.8% before 
surgery and 3.7 ± 3.6% after surgery. Hemodynamics test-
ing showed a marked improvement following SAA, and 
normal hemodynamics were maintained for at least 24 
months, which was consistent with previously reported re-
sults12. The 12 patients with TIA were followed-up for sev-
en to 36 months post-operatively, and the results showed 
significant improvement. Except for one patient who de-
veloped TIA seven months after surgery, similar symp-
toms and cerebrovascular events were not observed in the 
remaining patients. In the 14 patients with cerebral infarc-
tion, neurological function was dramatically improved 
post-operatively. Only one patient developed deteriora-
tion of original symptoms at 16 months after surgery, and 
re-examination with DSA showed the degree of stenosis 
was similar to that immediately after surgery. This may be 
related to the falling of emboli in other sites. Improvement 
was achieved following intensive therapy.
SAA is an effective method for the treatment of SVAS, 
but still presents a risk for rupture, artery dissection, per-
forating artery occlusion, thrombosis, cerebral hyperpefu-
sion, and re-stenosis13-15, which may be associated with the 
Table 1 – The blood velocity (Vm) of basilar and vertebral arteries before surgery and one week and three, six, 12, and 
24 months after surgery (cm/sec)
Before surgery 1 week 3 months 6 months 12 months 24 months
Basilar 111.58 ± 8.48* 67.57 ± 7.00 68.57 ± 4.54 62.43 ± 7.09 66.17 ± 9.20 59.00 ± 7.81
Vertebral 100.42 ± 9.50* 51.42 ± 5.44 55.68 ± 5.88 47.79 ± 5.46 50.40 ± 4.81 54.75 ± 5.24
*Compared with other periods, p < 0.01.
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sample selection, therapeutic regimen, and experience of 
clinicians. In the present study, peri-operative complica-
tions did not occur, which may be attributed to the simple 
lesions in these patients, good preparation before surgery, 
and small sample size. 
It has been reported that the incidence of re-stenosis 
was as high as 32.4% within six months after surgery13, 
and some patients with re-stenosis were even asymptom-
atic. In the present study, two patients were found to have 
developed stenosis among seven patients receiving DSA, 
but both were asymptomatic, which may be related to the 
mild degree of stenosis (20% and 35%, respectively). In 
one patient, the stenosis may be attributed to the large di-
ameter of the stent, which results in the over-expansion of 
the affected artery and subsequent hyperplasia of intima. 
Although SAA has some complications, the incidence of 
these complications is relatively low, and some complica-
tions can be avoided with the accumulation of experience. 
Currently, large randomized controlled studies on en-
dovascular stenting for symptomatic basilar artery steno-
sis are still lacking16,17. The Carotid and Vertebral Artery 
Transluminal Angioplasty Study (CAVATAS), the only 
randomized study to date to compare outcomes after en-
dovascular and medical treatment for patients with verte-
bral artery stenosis, included only 16 such patients17,18, and 
there was no difference in outcomes among those treated 
by stenting or drug therapy. Presently, there are mostly 
retrospective studies on the vertebrobasilar artery stenosis 
treated with SAA. Although the evidence of these findings 
cannot be compared to that of evidence-based random-
ized controlled studies, SAA for vertebrobasilar artery 
stenosis has some advantages such as a high success rate, 
fewer complications, prevention of recurrent stroke, and 
better short-term clinical improvement16,19. Overall, SAA 
is safe and effective. Following SAA, the degree of stenosis 
is significantly improved and the hemodynamics returns 
to normal. Follow-up also confirms the favorable long-
term effectiveness.
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